Controlling the cytokine storm by insulin: Glycogen synthase kinase-3 as a target in systemic inflammation*
- 1 May 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 34 (5), 1567-1569
- https://doi.org/10.1097/01.ccm.0000216192.11019.46
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: Role of glycogen synthase kinase-3β inhibition*Critical Care Medicine, 2006
- Glycogen Synthase Kinase 3β Functions To Specify Gene-Specific, NF-κB-Dependent TranscriptionMolecular and Cellular Biology, 2005
- GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat*Critical Care Medicine, 2005
- GSK3: an in-Toll-erant protein kinase?Nature Immunology, 2005
- Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3Nature Immunology, 2005
- GSK3 inhibitors: development and therapeutic potentialNature Reviews Drug Discovery, 2004
- The glamour and gloom of glycogen synthase kinase-3Trends in Biochemical Sciences, 2004
- Monocyte Survival Factors Induce Akt Activation and Suppress Caspase-3American Journal of Respiratory Cell and Molecular Biology, 2002
- Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activationNature, 2000
- Immunopharmacology: anti-inflammatory therapy targeting transcription factorsEuropean Journal of Pharmacology, 1999